GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cascadian Therapeutics Inc (FRA:3O61) » Definitions » 12-1 Month Momentum %

Cascadian Therapeutics (FRA:3O61) 12-1 Month Momentum % : 103.32% (As of May. 03, 2024)


View and export this data going back to . Start your Free Trial

What is Cascadian Therapeutics 12-1 Month Momentum %?

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-05-03), Cascadian Therapeutics's 12-1 Month Momentum % is 103.32%.

The industry rank for Cascadian Therapeutics's 12-1 Month Momentum % or its related term are showing as below:

FRA:3O61's 12-1 Month Momentum % is not ranked
in the Biotechnology industry.
Industry Median: -20.67 vs FRA:3O61: 103.32

Competitive Comparison of Cascadian Therapeutics's 12-1 Month Momentum %

For the Biotechnology subindustry, Cascadian Therapeutics's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cascadian Therapeutics's 12-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cascadian Therapeutics's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Cascadian Therapeutics's 12-1 Month Momentum % falls into.



Cascadian Therapeutics  (FRA:3O61) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %=( Price 1-month ago / Price 12-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cascadian Therapeutics  (FRA:3O61) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.


Cascadian Therapeutics 12-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Cascadian Therapeutics's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.


Cascadian Therapeutics (FRA:3O61) Business Description

Traded in Other Exchanges
N/A
Address
Cascadian Therapeutics Inc is a clinical-stage biopharmaceutical company focusing in developing innovative therapeutic product candidates for the treatment of cancer. Its objective is to discover, develop and commercialize novel compounds that have the potential to improve the lives and outcomes of cancer patients. The company's clinical-stage product candidate includes ONT-380, an orally active and selective small molecule HER2 inhibitor. In addition, it is also engaged in developing preclinical product candidates in oncology using its Checkpoint kinase 1 kinase inhibitor and protocell technology. All the business activity of the firm is functioned through the region of United States.

Cascadian Therapeutics (FRA:3O61) Headlines

No Headlines